Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 6:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Enlarged Prostate (BPH) Clear all
Terminated Phase 2 Interventional

Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

NCT00237536
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Lonidamine
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
65 Years to 80 Years · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
34
States / cities
Tucson, Arizona • Atherton, California • Culver City, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2009 · Synced Sep 14, 2026, 6:02 AM EDT
Completed Phase 1Phase 2 Interventional

Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)

NCT01454349
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
PRX302, Placebo
Drug
Lead sponsor
Sophiris Bio Corp
Industry
Eligibility
50 Years to 80 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Laguna Hills, California • Long Beach, California • Newport Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Sep 14, 2026, 6:02 AM EDT
Not listed Phase 1 Interventional

Study of the Effects of Pomegranate Tablets on Enlarged Prostates

NCT00381108
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Placebo Tablet, Pomegranate Tablet
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Long Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2010 · Synced Sep 14, 2026, 6:02 AM EDT
Completed Phase 3 Interventional

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH

NCT01966614
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
PRX302, Placebo
Drug · Other
Lead sponsor
Sophiris Bio Corp
Industry
Eligibility
50 Years and older · Male only
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
45
States / cities
Huntsville, Alabama • Anchorage, Alaska • Laguna Hills, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Sep 14, 2026, 6:02 AM EDT
Completed Not applicable Interventional Results available

3D Rotational CT Angiogram With Embolization Guidance and CBCT in Prostatic Artery Embolization

NCT03164629
View directory record Official record
Conditions
Enlarged Prostate
Interventions
cone-beam CT 3D Emboguide
Device
Lead sponsor
University of Miami
Other
Eligibility
50 Years to 79 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Sep 14, 2026, 6:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating the Clinical Efficacy of Thulio vs. Holmium Laser Enucleation of the Prostate

NCT07187180
View directory record Official record
Conditions
BPH With Symptomatic Lower Urinary Tract Symptoms, BPH With Urinary Obstruction
Interventions
holmium laser, pulsed thulium laser
Device
Lead sponsor
Smita De
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 14, 2026, 6:02 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms

NCT01139762
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Enlarged Prostate
Interventions
Tadalafil, Placebo, Finasteride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Davis, California • Fresno, California • Laguna Hills, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Sep 14, 2026, 6:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Moses 2.0 vs Magneto for HoLEP - a Randomized Controlled Trial

NCT07632742
View directory record Official record
Conditions
Enlarged Prostate (BPH), Benign Prostatic Hyperplasia
Interventions
Magneto 150 holmium laser, Moses 2.0 holmium laser
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 14, 2026, 6:02 AM EDT
Terminated Not applicable Interventional Results available

Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia

NCT01789840
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Embosphere Microspheres, TURP
Device · Procedure
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
50 Years to 79 Years · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
Long Beach, California • Los Angeles, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 14, 2026, 6:02 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Emsella for Reducing tSUI After HOLEP

NCT07580404
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms, Enlarged Prostate (BPH)
Interventions
Emsella chair
Device
Lead sponsor
Northwestern University
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 14, 2026, 6:02 AM EDT
Recruiting No phase listed Observational

Prospective Post Market Clinical Registry for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH Spring System Registry

NCT07538622
View directory record Official record
Conditions
BPH (Benign Prostatic Hyperplasia)
Interventions
Zenflow Spring System
Device
Lead sponsor
Zenflow, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Phoenix, Arizona • La Mesa, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 14, 2026, 6:02 AM EDT
Terminated No phase listed Observational

Holmium Laser Ablation of the Prostate (HoLAP) Versus KTP Laser Vaporization of the Prostate

NCT00169767
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Comparison study between KTP and HoLAP for BPH
Other
Lead sponsor
Indiana Kidney Stone Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Indianapolis, Indiana • Westland, Michigan • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2008 · Synced Sep 14, 2026, 6:02 AM EDT
Completed Phase 3 Interventional

Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

NCT00918983
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
NX-1207, Placebo
Drug
Lead sponsor
Nymox Corporation
Industry
Eligibility
45 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Sep 14, 2026, 6:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ejaculatory-Sparing HoLEP vs Standard HoLEP

NCT07631286
View directory record Official record
Conditions
Enlarged Prostate (BPH), Enlarged Prostate With Lower Urinary Tract Symptoms
Interventions
Ejaculatory-sparing (ES-sparing) HoLEP
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 14, 2026, 6:02 AM EDT
Completed Phase 3 Interventional Results available

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk

NCT00056407
View directory record Official record
Conditions
Neoplasms, Prostate
Interventions
Dutasteride, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 75 Years · Male only
Enrollment
8,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
297
States / cities
Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 236 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 14, 2026, 6:02 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)

NCT01912339
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptom
Interventions
Rezum System, Rigid Cystoscopy
Device · Procedure
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
50 Years and older · Male only
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
15
States / cities
Tucson, Arizona • Denver, Colorado • Aventura, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Sep 14, 2026, 6:02 AM EDT
Completed Phase 3 Interventional

Clinical Trial in Males With BPH (Enlarged Prostate)

NCT00029822
View directory record Official record
Conditions
Urinary Retention, Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Interventions
Alfuzosin (SL770499)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older · Male only
Enrollment
1,522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
35
States / cities
Huntsville, Alabama • La Mesa, California • San Bernardino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2008 · Synced Sep 14, 2026, 6:02 AM EDT
Recruiting Not applicable Interventional

A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms

NCT06849258
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
FloStent, Sham (Control)
Device
Lead sponsor
Rivermark Medical
Industry
Eligibility
45 Years and older · Male only
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
19
States / cities
Bakersfield, California • Beverly Hills, California • La Mesa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 14, 2026, 6:02 AM EDT
Terminated Not applicable Interventional Results available

Prostatic Artery Embolization vs Medication for Benign Prostatic Hyperplasia

NCT04398966
View directory record Official record
Conditions
BPH, Enlarged Prostate (BPH), Prostatic Hyperplasia
Interventions
Prostatic Artery Embolization (HydroPearl® compressible microspheres)
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 14, 2026, 6:02 AM EDT
Completed Phase 3 Interventional

Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018

NCT00945490
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
NX-1207, Placebo
Drug
Lead sponsor
Nymox Corporation
Industry
Eligibility
45 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
35
States / cities
Laguna Hills, California • San Diego, California • Tarzana, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 14, 2026, 6:02 AM EDT
Completed Not applicable Interventional Results available

Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia

NCT03055624
View directory record Official record
Conditions
Prostatic Hyperplasia, Benign, Enlarged Prostate With Lower Urinary Tract Symptoms
Interventions
Embosphere microparticles for prostate artery embolization
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 85 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 14, 2026, 6:02 AM EDT
Completed Phase 3 Interventional

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

NCT01438775
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
NX-1207
Drug
Lead sponsor
Nymox Corporation
Industry
Eligibility
45 Years and older · Male only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
28
States / cities
Huntsville, Alabama • Atherton, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Sep 14, 2026, 6:02 AM EDT
Active, not recruiting No phase listed Observational

Laser Prostatectomy Database and Registry

NCT00159406
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Enlarged Prostate
Interventions
Registry and Database
Other
Lead sponsor
Indiana Kidney Stone Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Sep 14, 2026, 6:02 AM EDT
Terminated Phase 2 Interventional Results available

A Study in Men With Benign Prostatic Hyperplasia

NCT01097707
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
LY500307, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
40
States / cities
Huntsville, Alabama • Anchorage, Alaska • Glendora, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Sep 14, 2026, 6:02 AM EDT